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Pioneer works on therapeutic hypothermia (TH) half a century ago already showed promising results but clinical 
application was limited by a lack of understanding of the underlying pathophysiology, lack of reliable method for 
temperature control and lack of intensive care facilities to deal with possible complications. More recently, 2 studies 
in 2002 supported the application of moderate TH (32.0-34.0
oC) in post-cardiac arrest patients. Although the studies 
included only patients suffering from out-of-hospital VF, many ICUs world-wide are applying the therapy to all 
post-cardiac arrest patients irrespective of site or presenting rhythm. While primary coagulopathy and cardiogenic 
shock are usually stated as relative contraindications, evidences are accumulating to support the application of 
TH in patients with cardiogenic shock. TH can be divided into 4 phases: Induction, maintenance, de-cooling and 
normothermia. Induction is usually achieved by infusion of cold isotonic fluid. The precautions included avoidance 
of over-cooling, hypokalaemia, hyperglycaemia, and shivering. TH can be maintained by many different methods, 
varying in their level of invasiveness, cost and effectiveness. Issues including changes in pharmacokinetics and 
haemodynamics, and susceptibility to infection need to the addressed. The optimal duration of maintenance is 
unknown but the usual practice is 12-24 hours. De-cooling and rewarming is especially challenging because 
complications can be serious if temperature rise by more than 1
oC every 3-5 hours. Life-theatening hyperkalaemia 
can occur especially if patient suffers from renal insufficiency. Fever is a frequent complication either due to infection or 
post-cardiac arrest syndrome but patient must be kept normothermic for 72 hours. (Korean J Anesthesiol 2010; 59: 299-
304)
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Introduction
    Although the basic principles of resuscitation were 
described by Versalius more than 500 years ago, the practice of 
cardiopulmonary resuscitation in its modern form only starts 
50 years ago [1,2]. Despite advances in the understanding 
and practices of airway management, ventilatory support, 
external cardiac compression and drug therapy the outcome of 
patients undergoing cardiopulmonary resuscitation remained 
poor [3]. Patients may have spontaneous circulation restored 
and admitted to the intensive care unit, but then developed 
complications related to ischaemic insult to the brain as well 300 www.ekja.org
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as to the rest of the body. The term post-resuscitation disease 
was coined by the Russian resuscitologist Vladimir A. Negovsky 
in 1972 to describe the constellation of pathological processes 
caused by ischaemia and reperfusion associated with cardiac 
arrest and the subsequent resuscitation. This is more recently 
renamed post-cardiac arrest syndrome [4] because “the term 
resuscitation is now used more broadly to include treatment of 
various shock states in which circulation has not ceased…(and) 
the term postresuscitation implies that the act of resuscitation 
has ended…”4 key components contribute to the development 
of this syndrome: 1) post-cardiac arrest brain injury; 2) post-
cardiac arrest myocardial dysfunction; 3) systemic ischaemia/
reperfusion response; and 4) persistent precipitating pathology 
[4]. There is evidence to support that proper management in the 
post-resuscitation phase can improve outcome of these patients 
[5] and therapeutic hypothermia is one important component 
of such management. 
    To avoid confusion, there is a need to define terminology used 
in relation to manipulation of body temperature [6]:
   • Hypothermia is defined as core body temperature of less 
then 36
oC regardless of the cause.
    • Induced hypothermia is defined as an intentional reduction 
of a patient’s core temperature below 36
oC.
   • Therapeutic hypothermia is defined as controlled induced 
hypothermia; i.e. induced hypothermia with the potentially 
deleterious effects such a shivering, being controlled or 
suppressed.
   • Controlled or therapeutic normothermia is defined as 
bringing down core temperature in a patient with fever, and 
maintaining temperature within a range of 36-37.5
oC, with 
the potentially deleterious effects such a shivering, being 
controlled or suppressed.
    The degree of therapeutic hypothermia can mild (34.0-
35.9
oC), moderate (32.0-33.9
oC), moderately deep (30.0-
31.9
oC) or deep (<30.0
oC) according to the target temperature 
as stated within the brackets. 
    Early studies showed that induced hypothermia improved 
outcome in cardiac arrest patients [7,8]. Although both studies 
were small (12 patients had induced hypothermia in each 
study) case series. However, further progress was hindered by 
1) lack of understanding of the underlying pathophysiology, 
2) lack of reliable methods to control body temperature, 
and 3) lack of intensive care facilities to manage possible 
complications. The early hypothesis that beneficial effect of 
hypothermia was due to reduction of metabolism leads to the 
adoption of more profound cooling (around 30
oC). The result 
was serious complications which cannot be handled effectively 
without the support of intensive care, which was then only at 
its infancy. Further studies in the recent decades showed that 
the mechanism of cerebral protection by hypothermia is more 
complicated and neurological outcome can be improved by 
mild to moderate degree of hypothermia. Two studies published 
in 2002 [9,10] provided the evidence basis that hypothermia 
can improve neurological outcome. Coupled with advances 
in technology in hypothermia and intensive care in general, 
therapeutic hypothermia is now a standard for management of 
post-cardiac arrest patient.
Indications and Contraindication
    The study population of both the study by Bernard et al. [9] 
and the HACA study Group [10] are patients suffering from 
out-of-hospital ventricular fibrillations. There is evidence 
that cooling patients with presenting rhythms other than VF 
or VT following out-of-hospital arrests does no harm [11]: 
2 retrospective cohort studies found that the outcomes for 
patients presenting with PEA/systole did not differ from those 
observed among the group presenting with VF or VT. There 
is little published evidence to support the use of therapeutic 
hypothermia following in-hospital cardiac arrest. An analysis of 
patients entered into Arrich and ERCHACARS Group [12] found 
that 13% of procedures were performed post in-hospital cardiac 
arrest. 43% of these were cooled and although the initiation of 
hypothermia was faster than that for the out-of- hospital arrests, 
there was no difference in outcome between the patients 
treated with hypothermia and those with normothermia. The 
HACA in-hospital multi-center trial is currently investigating 
whether therapeutic hypothermia is beneficial for patients 
following in-hospital cardiac arrest.
    In both the HACA and Bernard studies, patients who are 
hypotensive (MAP < 60 mmHg [10] or SBP < 90 mmHg 
despite adrenaline infusion [9]) were excluded. Coagulopathic 
patients were also excluded in the HACA Study Group [10]. 
The underlying reason being the possible deleterious effect 
of hypothermia on cardiovascular function and coagulation. 
However, there are several publications suggesting that post-
cardiac arrest patients in cardiogenic shock could actually also 
benefit from moderate therapeutic hypothermia [11,13]. 
    Reduction in platelet count and platelet dysfunction is noted 
when body temperature is dropped to <35
oC; and when 
temperature is below 33
oC, synthesis and kinetics of clotting 
enzymes and plasminogen activator inhibitors are also affected 
[14]. However, it was found in a recent study which assessed 
the risk and severity of bleeding during simultaneous use of 
mild hypothermia and thrombolysis that bleeding risks were 
similar to historical controls treated with thrombolytics alone, 
although there was a trend toward more red blood cell units 
being required to reach target hematocrit in hypothermic 
patients who developed bleeding complications and needed 
transfusions [15]. This, however, is a small study and more data 301 www.ekja.org
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is required. The current practice is still to avoid induction of 
hypothermia in patients with coagulopathy. 
    The procedures of therapeutic hypothermia can be divided 
into 4 phases: induction, maintenance, de-cooling (or re-
warming) and normothermia.
Induction
    This is the initial phase during which the patient’s body 
temperature is lowered to the target of 32-34
oC. Continuous 
core temperature measurement should be started before 
induction of therapeutic hypothermia to ensure that the 
patient’s body temperature is within the target range and to 
avoid overshoot. This is preferably achieved by bladder, rectal, 
central venous, or oesophageal measurement. However, it 
should be noticed that bladder temperature may poorly reflect 
core temperature if the patient is oliguric, and other monitoring 
sites are preferred.
    This phase is associated with many possible complications 
most of which can be minimized by rapid cooling. Rapid 
cooling can be achieved by rapid bolus administration of 30 
to 40 ml/kg cold (4°C) isotonic resuscitation fluid over 1 hour. 
Despite theoretical problems this method is proven to be safe 
[16]. 
    When core temperature drops to 32°C, metabolic rate 
decreases to 50-65% of normal. Oxygen consumption and 
carbon dioxide production are reduced accordingly. It is 
important to adjust ventilator settings to avoid hypocapnia. The 
issue of how to interpret arterial blood gases in hypothermic 
patients (alpha-stat versus pH-stat) is a topic of some contro-
versy and readers are referred to review articles for detailed 
discussion [17]. Cold-induced diuresis is common in these 
patients and can lead to hypovolemia. This may be related to 
increased venous return, tubular dysfunction and hormonal 
changes [14]. Hypothermia can lead to hypokalaemia, hypo  pho-
sphataemia and hypomagnesaemia as a result of intracellular 
shift as well as urinary loss because of tubular dysfunction. It 
is particularly important to monitor and replace potassium in 
order to avoid arrhythmia [18]. On the other hand, mild meta-
bolic acidosis is common yet do not usually require treatment. 
It is the result of increased fat metabolism, leading to an 
increase in the levels of glycerol, free fatty acids, ketonic acids, 
and lactate. pH rarely fall below 7.25 [19]. Hyperglycaemia due 
to reduction of insulin secretion and insulin resistance should 
be controlled by close monitoring and insulin therapy. 
    The haemodynamic effect of hypothermia is more complicated. 
The main sources of relevant data come from patients with 
hypothermia induced during cardiac surgery. All patients 
studied developed bradycardia but blood pressure usually 
remained stable. Cardiac output decreased along with the heart 
rate; however, the hypothermia-induced decrease in metabolic 
rate usually equaled or exceeded the decrease in cardiac output, 
so that the balance between supply and demand remained 
constant or improved [20]. However, the actual cardiac output 
is also affected by the volume status and effect of sedation. 
Systolic function of myocardium may actually be improved 
during mild to moderate hypothermia but diastolic function 
is usually impaired. It is important to note that the effect of 
hypothermia on myocardial contractility is strongly dependent 
on heart rate. If the heart rate is allowed to decrease along 
with the temperature, myocardial contractility as measured 
by systolic function usually increases, although there may be a 
mild degree of diastolic dysfunction. However, if the heart rate 
is artificially increased through administration of chronotropic 
drugs or a pacing wire, myocardial contractility decreases 
signifi  cantly. This phenomenon has been demonstrated in 
animal studies and also in patients undergoing cardiothoracic 
surgery. Thus, the effect of hypothermia on myocardial function 
strongly depends on whether the heart rate is allowed to 
decrease [20-22]. Maintaining euvolemia is one important 
aspect of management during therapeutic hypothermia 
and one challenge is cold induced diuresis. The underlying 
mechanisms leading to cold-induced diuresis include 
increased venous return caused by constriction of peripheral 
vessels (particularly in the skin) due to hypothermia-induced 
increases in plasma noradrenaline levels and activation of 
the sympathetic nerve system, activation of atrial natriuretic 
peptide, decreased levels of antidiuretic hormone and renal 
antidiuretic hormone receptor levels, and tubular dysfunction 
[23,24]. If uncorrected, diuresis can cause hypotension as well 
as electrolyte depletion and increase in blood viscosity. The 
risk for hypovolemia increases significantly if the patient is 
simultaneously treated with diuretic agents such as mannitol. 
However, hypotension can be quite easily prevented by avoiding 
or promptly correcting hypovolemia, and by avoiding excessive 
stimulation of heart rate. While profound hypothermia of 
<28
oC is associated with severe arrhythmia, mild to moderate 
hypothermia could stabilize membranes. One study showed 
that mild and moderate hypothermia actually improves success 
of defibrillation [25].
    Hypothermia will activate homeostatic mechanisms of 
the body: vasoconstriction and shivering. Study in normal 
human showed that the threshold for vasoconstriction is 
about 36.5
oC and that for shivering is 35.5
oC. The threshold 
is slightly higher in female but the difference is <0.5
oC [26]. 
Shivering of postoperative patients may lead to increased 
risk of morbid cardiac events especially in older patients with 
heart disease: the result of increased rate of metabolism and 
oxygen consumption, leading to excess work of breathing and 
tachycardia [27,28]. However, the situation may be different 302 www.ekja.org
Therapeutic hypothermia Vol. 59, No. 5, November 2010
in sedated patients. While hypothermia in an awake patient 
causes tachycardia, inducing hypothermia intentionally in 
sedated patients has the opposite effect. Shivering will increase 
oxygen consumption, but as the patient is on mechanical 
ventilation, there will be no increase in the work of breathing 
[29]. Nevertheless, it is important to prevent or aggressively 
treat shivering because it significantly complicates hypothermia 
induction, and leads to an undesirable increase in metabolic 
rate and oxygen consumption. 
    Shivering may be controlled by one and more of the following 
methods: 1) drugs lowering shivering threshold, e.g. aceta-
minophen (paracetamol), aspirin, and nonsteroidal anti-
infla  m  matory drugs; 2) drugs suppressing shivering response 
paraly  zing agents, sedatives, opiates, and others; and/or 3) 
skin counterwarming. Drugs lowering shivering threshold 
are not quite effective in general. Of the drugs which suppress 
shivering, meperidine is the most effective [30]. In a recent 
systematic review, it was found that there is significant variation 
in sedation protocols amongst the 68 ICUs included in the 
selected studies [31]. Midazolam (5 mg/h to 0.3 mg/kg/h) being 
most commonly used, followed by propofol (up to 6 mg/kg/h). 
A quarter of ICUs do not use any analgesic, the rest use either 
fentanyl (0.5-10 mcg/kg/h) or morphine. Most ICUs routinely 
use neuromuscular blocking agents. Use of neuromuscular 
blocking agents, however, is associated with several 
disadvantages some of which can be reduced by adequate 
sedation: 1) attempts of the brain to generate a shivering 
response will not cease; 2) they can mask seizure; 3) they lack 
of vasodilating effect of sedatives; and 4) their use is associated 
with development of critical illness polyneuromyopathy 
[14]. The importance of adequate sedation and suppression 
of hypothermia-induced stress responses is underscored by 
observations from animal experiments suggesting that some or 
all of hypothermia’s neuroprotective effects can be lost if cooling 
is used in non-sedated animals [32]. Skin counterwarming is 
an interesting phenomenon. It was found that 4
oC increase 
in skin temperature could “compensate” for 1
oC drop in core 
temperature to prevent a shivering response. Some areas of 
the body (hands, feet and face) have a higher concentration 
of “temperature sensors” and warming of those areas could 
have a greater effect on suppressing shivering [33]. By reducing 
shivering, counterwarming can reduce metabolic rate and 
oxygen consumption of hypothermic patients [34]. 
Maintenance
    During this phase, the goal is to maintain core temperature 
at 32-34
oC for 12-24 hours [9,10]. The patient is usually 
more stable during this phase with fewer disturbances in their 
haemodynamic, volume or electrolyte status, as well as less 
shivering. However, the patient is subjected to other hazards 
including changes in pharmacokinetics, nosocomial infections 
and bedsores. 
    Conventionally, patients are maintained cool by surface 
cooling through exposure, placing ice packs to the neck, 
groins and axillae, and/or spraying with water. Rubber cooling 
blankets can also be used but should be placed over the 
patient. Placing those blankets under the patient can lead to 
skin damage due to vasoconstriction in already pressurized 
areas. Although widely available and inexpensive, conventional 
surface cooling is difficult to control as there is no internal 
feedback mechanism. Overcooling is common despite extreme 
nursing vigilance. Nursing workload can also be high. This has 
brought about the emergence of many commercial cooling 
devices. These may be classified as non-invasive surface cooling 
devices such as hydrogel-coated water circulating pads or 
water-circulating wrapping garments, and invasive core cooling 
devices using intravascular catheters. A problem with surface 
cooling is that 40-90% the patient’s surface area needs to be 
covered and carries a risk of skin lesions. But they can be started 
immediately using nurse-driven protocols without direct 
physician intervention. Cooling rate is 1.0-1.5
oC/hour. Core-
cooling methods, on the other hand, are highly reliable once 
the catheter is in place, with a cooling rate of 2.0-4.5
oC/hour. 
However, insertion of catheter is required and it can lead to 
complications such as thrombosis and infection [35]. 
    Cautious medication dosing during this phase is required due 
to change in drug metabolism. For example, CYP450 activity has 
been found to be temperature dependent [36]. Hypothermia 
can increase the risk of infection. Even short duration of 
hypothermia during perioperative period for intracranial 
aneurysm increase the risk of postoperative bacteraemia [37]. 
A study has shown that 3 days of prophylaxis with ampicillin-
sulbactam can reduce early onset nosocomial pneumonia but 
not the incidence of late-onset nosocomial pneumonia [38]. 
Nursing care to prevent bedsore is important. Sedation should 
be continued during this phase.
De-cooling/Rewarming
    After 12-24 hours of cooling, patient can be allowed to warm 
up slowly. The goal should be 0.2-0.33
oC per hour until the 
patient is 36.5-37.0 
oC. More rapid warming must be prevented 
to avoid electrolyte disturbance due to transcellular shift, 
hypoglycaemia due to increased insulin sensitivity, as well as 
aggravated brain destruction [35]. 
    Hyperkalaemia can develop during this phase due to release 
of intracellular potassium. This can be prevented by slow rewar-
ming, allowing the kidneys to excrete the excess potassium. 
However, this should not be a reason to accept hypokalaemia 303 www.ekja.org
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in the induction or maintenance phase. For patients with renal 
dysfunction, renal replacement therapy should be started 
before rewarming to avoid life-threatening hyperkalaemia. 
Normothermia
    Fever can develop after cessation of cooling. This may be the 
result of nosocomial infection or part of the post-cardiac arrest 
syndrome. Fever is independently linked to adverse outcome in 
all types of neurological insults. Furthermore, cerebrovascular 
reactivity may be impaired following hypothermia treatment 
and thus increase the potential harmful effects of fever 
even more [38,39]. There was a case report in which a post-
cardiac arrest patient who initially improved after rewarming 
deteriorated after development of fever and subsequently died. 
Autopsy showed massive brain swelling and tentorial herniation 
[40]. It is recommended that patients should be maintained 
normothermic after decooling until 72 hours have elapsed 
since restoration of spontaneous circulation [35]. Patients who 
develop fever should be actively cooled again. 
Conclusion
    Current evidence supports that induction of therapeutic 
hypothermia in selected patients after cardiac arrest can 
improve neurological outcome [41]. However, not all ICUs are 
currently taking up the practice. Lack of familiarity and lack 
of a concrete protocol are the most important amongst the 
list of perceived barriers [42]. It is hoped that by summarizing 
the current state of knowledge on the subject and highlighting 
issues on clinical management will enable more patients to 
benefit from the therapy. 
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